Immunotherapy combo aims to outperform standard care in advanced liver cancer

NCT ID NCT04723004

Completed Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 3 trial compares a combination of two drugs—toripalimab (an immunotherapy) and bevacizumab (an anti-angiogenic agent)—against the standard drug sorafenib as the first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolls adults aged 18–75 who have not received prior systemic therapy. Researchers are measuring how long participants live without their cancer worsening and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab combined with bevacizumab
What this could lead to: If successful, this combination could become a new first-line treatment option for advanced liver cancer, potentially improving survival and delaying disease progression.
What could go wrong: This is an early-phase trial with a limited number of participants. The combination may not prove superior to sorafenib, and side effects from immunotherapy and anti-angiogenic drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Show contact details

Locations

Anhui Cancer Hospital

Hefei, Anhui, 230000, China
Anhui Provincial Hospital

Hefei, Anhui, 230000, China
Army Medical Center of PLA

Chongqing, Chongqing Municipality, 400000, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100000, China
Changhua Christian Hospital

Zhanghua, Taiwan, 000500, China
China PLA General Hospital

Beijing, Beijing Municipality, 100000, China
Curie Oncology

Singapore, Singapore, 999002, Singapore
First Affiliated Hospital of Xian Jiaotong University

Xi’an, Shanxi, 710000, China
Gansu Wuwei Tumor Hospital

Wuwei, Gansu, 733000, China
Hainan General Hospital

Haikou, Hainan, 570100, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150000, China
Henan Provincial Cancer Hospital

Zhengzhou, Henan, 450000, China
Hubei Cancer Hospital

Wuhan, Hubei, 430000, China
Hunan Cancer Hospital

Changsha, Hunan, 410000, China
Jia Fan

Shanghai, 130061, China
Jilin Cancer Hospital

Changchun, Jilin, 130000, China
Jilin Guowen Hospital

Changchun, Jilin, 130000, China
Kaohsiung Medical University Chung-Ho Memorial Hospital

Gaoxiong, Taiwan, 000800, China
Liaoning cancer hospital

Shenyang, Liaoning, 110000, China
MacKay Memorial Hospital

Taibei, Taiwan, 100, China
NanJing Drum Tower Hospital

Nanjing, Jiangsu, 210000, China
Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, 510000, China
Nantong Tumor Hospital

Nantong, Jiangsu, 226000, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100000, China
SSun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510000, China
Shandong Cancer Hospital

Jinan, Shandong, 250000, China
ShuLan（HangZhou) Hospital

Hangzhou, Zhejiang, 310000, China
Sichuan Cancer Hospital

Chengdu, Sichuan, 610000, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510000, China
Tan Tock Seng Hospital

Singapore, Singapore, 999002, Singapore
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266000, China
The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221000, China
The First Affiliated Hospital of Bengbu Medical college

Bengbu, Anhui, 233000, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400000, China
The First Affiliated Hospital of Gannan Medical University

Ganzhou, Jiangxi, 341000, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China
The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510000, China
The First Affiliated Hospital,Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China
The First Peoples Hospital of Foshan

Foshan, Guangdong, 528000, China
The Frist Hospital of Lanzhou University

Lanzhou, Gansu, 730000, China
The Second Affiliated hospital of Nanchang University

Nanchang, Jiangxi, 330000, China
The Second Hospital of Anhui Medical University

Hefei, Anhui, 230000, China
The Southwest Hospital Of AMU

Chongqing, Chongqing Municipality, 400000, China
The first Affiliated hospital of Nanchang University

Nanchang, Jiangxi, 330000, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 300000, China
Tongji Hospital Tongji Medical College Of HUST

Wuhan, Zhejiang, 430000, China
West China Hospital，Sichuan University

Chengdu, Sichuan, 610000, China
Xi'an International Medical Center Hospital

Xi’an, Shanxi, 710000, China
Xiangya Hospital of Central South University

Changsha, Hunan, 410000, China
Xiehe Hospital Tongji Medical College Of HUST

Wuhan, Zhejiang, 430000, China
Yuebei People's Hospital

Shaoguan, Guangdong, 512000, China
Yunnan Cancer Hospital

Kunming, Yunnan, 650000, China
ZheJiang Cancer Hospital

Hangzhou, Zhejiang, 310000, China
ZheJiang Provincial People's Hospital

Hangzhou, Zhejiang, 310000, China
Zhongnan Hospital of Wuhan University

Wuhan, Zhejiang, 430000, China
he First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.